Richard Chesworth
Keine laufenden Positionen mehr
Karriereverlauf von Richard Chesworth
Ehemalige bekannte Positionen von Richard Chesworth
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KYMERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.08.2020 | 22.10.2021 |
| EPIZYME, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Richard Chesworth
| Imperial College London | Undergraduate Degree |
| University of Oxford | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Vereinigtes Königreich | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Richard Chesworth
- Erfahrung
